What should investors who are experiencing Nasdaq market whiplash do now? Alphabet is now quite reasonably valued with a price-to-earnings-to-growth (PEG) ratio of 1.04, based on data from LSEG.

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.

“The FDA approval of suzetrigine (Journavx) opens the door to a new class of oral systemic medications for patients who suffer from acute pain, including pain after surgery,” says Dr. Edward ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Heading into 2025, an even bigger game changer for the company may be Journavx, approved in January by the FDA as the first oral non-opioid painkiller in its class. Journavx taps into a massive ...